Title: Oligomeric Compounds Effecting Drosha-Mediated Cleavage
Filed: Sept. 20, 2005
Lead Inventor: Richard Griffey, Isis Pharmaceuticals
The invention, the patent application's abstract states, "provides methods of promoting Drosha-mediated cleavage of antisense oligomeric compounds and compositions and compounds for carrying out the same."
Title: Therapeutic Alteration of Transplantable Tissues Through In Situ or Ex Vivo Exposure to RNA Interference Molecules
Filed: July 11, 2005
Lead Inventor: Timothy Kowalik, University of Massachusetts
According to the patent application's abstract, the invention, "at least in part, relates to the discovery of efficacious delivery of an RNAi agent (in preferred aspects of the invention, an siRNA) to a transplantable tissue. Organ rejection, transplantation-mediated transmission of viral infection, and triggering of apoptosis in transplanted tissues can each be minimized by the methods and compositions of the instant invention," the abstract states. "The RNAi agent(s) of the instant invention can be delivered as 'naked' molecules, or using liposomal and other modes of delivery, to transplantable tissues. Such delivery can occur via perfusion of the RNAi agent in solution through the vasculature of a whole or partial organ; or tissues including transplantable cells and cell lines may be bathed, injected or otherwise treated with RNAi agents. Preferred transplantable tissues include, for example, pancreas, liver, kidney, heart, lung, and all cells and cell lines derived from such tissues (e.g., pancreatic islet cells that may, e.g., be transplanted as a treated population)," it adds.
Title: IKKalpha- and IKKbeta-Specific Inhibitors
Filed: Sept. 30, 2005
Lead Inventor: Jun Li, Boehringer Ingelheim
The invention, the patent application's abstract states, comprises a method for modulating NF-kappaB dependent gene transcription in a cell comprised of modulating IKKalpha and IKKbeta protein and protein activity in the cell. The … invention also provides siRNA compositions and methods thereof for modulating NF-kappaB dependent gene transcription."